Laporan Laba Rugi (TTM)
Laporan Laba Rugi Humacyte, Inc. - Equity Warrant menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.
Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.
|
2020 12-31 |
2021 03-31 |
2021 06-30 |
2021 09-30 |
2021 12-31 |
2022 03-31 |
2022 06-30 |
2022 09-30 |
2022 12-31 |
2023 03-31 |
2023 06-30 |
2023 09-30 |
2025 03-31 |
2025 06-30 |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 2 | 2 | 1 | 0 | 0 | 1 | 1 |
| Change (%) | -6.71 | 35.37 | -35.74 | 4.38 | 6.18 | 45.56 | -10.76 | -10.16 | -14.89 | -97.67 | -100.00 | ∞ | 58.22 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | |
| Cost Of Sales | 54 | 55 | 58 | 58 | 61 | 63 | 63 | 65 | 1 | 2 | 70 | 71 | 83 | 81 |
| Change (%) | 1.43 | 5.00 | 1.20 | 5.23 | 1.92 | 0.13 | 3.12 | -98.40 | 93.23 | 3,409.11 | 1.73 | 16.23 | -1.85 | |
| % of Revenue | 3,626.96 | 3,943.28 | 3,058.74 | 4,817.36 | 4,856.77 | 4,662.04 | 3,207.07 | 3,705.68 | 66.07 | 150.00 | 226,167.74 | 16,034.82 | 9,946.94 | |
| Gross Operating Profit | -53 | -53 | -56 | -57 | -60 | -61 | -61 | -63 | 1 | -1 | -70 | -71 | -82 | -81 |
| Change (%) | 1.66 | 4.21 | 2.45 | 5.25 | 1.83 | -0.86 | 3.56 | -100.85 | -225.42 | 10,422.67 | 1.78 | 15.50 | -2.23 | |
| % of Revenue | -3,526.96 | -3,843.28 | -2,958.74 | -4,717.36 | -4,756.77 | -4,562.04 | -3,107.07 | -3,605.68 | 33.93 | -50.00 | -226,067.74 | -15,934.82 | -9,846.94 | |
| SG&A | 12 | 14 | 16 | 18 | 21 | 22 | 22 | 23 | 23 | 22 | 20 | 20 | 29 | 31 |
| Change (%) | 12.74 | 19.69 | 12.11 | 16.27 | 4.24 | -0.96 | 3.62 | 1.23 | -1.96 | -9.34 | -0.58 | 41.54 | 7.21 | |
| % of Revenue | 805.70 | 973.62 | 860.86 | 1,501.90 | 1,673.00 | 1,642.43 | 1,117.52 | 1,297.59 | 1,462.17 | 1,684.31 | 65,609.68 | 5,535.98 | 3,751.10 | |
| R&D | 62 | 62 | ||||||||||||
| Change (%) | 0.00 | |||||||||||||
| % of Revenue | 3,976.10 | 4,671.62 | ||||||||||||
| OpEx | 66 | 68 | 74 | 76 | 82 | 85 | 84 | 87 | 86 | 87 | 90 | 92 | 112 | 112 |
| Change (%) | 3.48 | 7.91 | 3.60 | 7.86 | 2.51 | -0.15 | 3.25 | -1.16 | 0.60 | 4.38 | 1.21 | 21.82 | 0.47 | |
| % of Revenue | 4,432.66 | 4,916.89 | 3,919.60 | 6,319.26 | 6,529.77 | 6,304.47 | 4,324.59 | 5,003.27 | 5,504.35 | 6,505.93 | 291,777.42 | 21,570.79 | 13,698.04 | |
| Operating Income | -65 | -67 | -72 | -75 | -81 | -83 | -82 | -85 | -85 | -85 | -90 | -92 | -111 | -111 |
| Change (%) | 3.72 | 7.34 | 4.63 | 7.91 | 2.46 | -0.89 | 3.58 | -0.98 | 0.89 | 5.97 | 1.25 | 21.25 | 0.21 | |
| % of Revenue | -4,332.66 | -4,816.89 | -3,819.60 | -6,219.26 | -6,429.77 | -6,204.47 | -4,224.59 | -4,903.27 | -5,404.35 | -6,405.93 | -291,677.42 | -21,470.79 | -13,598.04 | |
| Interest Expense | -2 | -2 | -3 | -3 | -4 | -5 | -6 | -6 | -6 | -6 | -7 | -7 | -10 | -10 |
| Change (%) | -1.09 | 30.30 | 23.08 | 24.48 | 20.68 | 5.20 | 7.92 | 4.08 | 4.31 | 3.43 | -2.66 | 60.67 | 0.29 | |
| % of Revenue | -147.69 | -156.58 | -150.72 | -288.68 | -344.26 | -391.28 | -282.79 | -341.96 | -396.17 | -485.51 | -21,577.42 | -2,023.40 | -1,282.52 | |
| Net Income | -67 | -69 | -71 | -85 | -26 | -26 | 28 | 34 | -12 | -29 | -89 | -89 | -78 | -59 |
| Change (%) | 3.95 | 3.35 | 19.31 | -68.95 | -1.77 | -207.88 | 22.39 | -134.84 | 143.23 | 204.71 | 0.81 | -13.12 | -24.47 | |
| % of Revenue | -4,461.70 | -4,971.32 | -3,795.59 | -7,047.44 | -2,096.36 | -1,939.45 | 1,437.40 | 1,971.30 | -764.54 | -2,184.83 | -286,051.61 | -15,022.44 | -7,171.27 | |
Source: Capital IQ
